Author(s):
Anannya Bose, Subhabrota Majumdar, AsimHalder
Email(s):
anannya.bose@jisuniversity.ac.in
DOI:
10.52711/0974-360X.2024.00276 
Address:
Anannya Bose1*, Subhabrota Majumdar2, AsimHalder3
1Department of Pharmaceutical Technology, JIS University, Kolkata -700109, West Bengal, India.
2Calcutta Institute of Pharmaceutical Technology & A.H.S, Uluberia, Howrah -711316, West Bengal, India.
3School of Pharmaceutical Technology, Adamas University, Kolkata -700126, India.
*Corresponding Author
Published In:
Volume - 17,
Issue - 4,
Year - 2024
ABSTRACT:
Glaucoma affects millions worldwide. Untreated, it might cause lifelong blindness. Traditional treatments have been limited and intrusive. Liposomes are changing glaucoma treatment. Phospholipid bilayer liposomes can carry medications for targeted administration. This innovative glaucoma medication has huge potential to transform the way we treat it. This essay will explain liposomes, how they function, and why they are a glaucoma therapy game-changer. Eyes have several sensory compartments. Eyes send brain impulses. Eye-aqueous humour production causes glaucoma. It mostly affects the over-50s. Glaucoma destroys retinal ganglion cells and the optic nerve, causing blindness. CO2 inhibitors treat it. This inhibitor keeps aqueous humour from the ocular fluid. Normal eye medication dosage. This ocular drug administration approach relies on nasolacrimal drainage and tears turnover to provide the usual dose form. Low bioavailability. Novel pharmaceutical delivery dose formulations can fix this. Nano co-adhesive compositions prolong ocular drug delivery. Liposomes cure glaucoma uniquely. Bioavailability lowers toxicity and dosage. Novel Drug Delivery System helps glaucoma patients worldwide. Liposomes drop IOP slowly. Aqueous liposomes have natural and synthetic phospholipid bilayers. Liposomes contain hydrophilic medicines. Liposomes resemble cells. Their properties make them cling to cells. Biocompatible liposomes increase drug solubility, stability, absorption, and toxicity. Conjunctiva and cornea interactions with liposomes impact tear dynamics and medication duration and frequency. Novel eye medication delivery methods are being investigated. This medicine administration at the proper place challenges drug delivery systems. Here are innovative ocular drug-delivery methods. Biocompatible liposomes improve drug solubility, stability, absorption, and toxicity. Liposomes affect tear dynamics and medication duration and frequency via interacting with the conjunctiva and cornea. Novel ocular medicine delivery techniques for various eye ailments are being explored. This medication administration at the right place challenges drug delivery systems. Innovative ocular drug-delivery systems will be reviewed here.
Cite this article:
Anannya Bose, Subhabrota Majumdar, AsimHalder. Liposomal drug delivery for glaucoma: Recent advancement in ocular therapy. Research Journal of Pharmacy and Technology.2024; 17(4):1741-7. doi: 10.52711/0974-360X.2024.00276
Cite(Electronic):
Anannya Bose, Subhabrota Majumdar, AsimHalder. Liposomal drug delivery for glaucoma: Recent advancement in ocular therapy. Research Journal of Pharmacy and Technology.2024; 17(4):1741-7. doi: 10.52711/0974-360X.2024.00276 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-4-50
REFERENCES:
1. Maulvi FA, Shetty KH, Desai DT, Shah DO, Willcox MDP. Recent advances in ophthalmic preparations: Ocular barriers, dosage forms and routes of administration. Int J Pharm. 2021; 608: 121105. doi:10.1016/j.ijpharm.2021.121105
2. Nayak K, Misra MA. Review on recent drug delivery systems for the posterior segment of the eye. Biomed Pharmacother. 2018; 107: 1564-1582. doi: 10.1016/j.biopha.2018.08.138
3. Mofidfar M, Abdi B, Ahadian S, Mostafavi E, Desai TA, Abbasi F. Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies. Int J Pharm. 2021; 607: 120924. doi:10.1016/j.ijpharm.2021.120924
4. Urs R, Ketterling JA, Yu ACH, Lloyd DO, You BY. Silverman RH. Ultrasound imaging and measurement of choroidal blood flow. Transl Vis Sci Technol. 2018; 7(5): 5. doi:10.1167/tvst.7.5.5
5. Huang HL, Wang GH, Wang KD, Sun XH. Publication trends of primary angle-closure disease during 1991-2022: a bibliometric analysis. Int J Ophthalmol. 2023; 16(5): 800-810. doi:10.18240/ijo.2023.05.19
6. Nsairat H, Khater D, Sayed U, Odeh F, Al Bawab A, Alshaer W. Liposomes: structure, composition, types, and clinical applications. Heliyon. 2022; 8(5): e09394. doi:10.1016/j.heliyon.2022.e09394
7. Nikolova MP, Kumar EM, Chavali MS. Updates on responsive drug delivery based on liposome vehicles for cancer treatment. Pharmaceutics. 2022; 14(10): 2195. doi:10.3390/pharmaceutics14102195
8. Mofidfar M, Abdi B, Ahadian S, Mostafavi E, Desai TA, Abbasi F. Drug delivery to the anterior segment of the eye: a review of current and future treatment strategies. Int J Pharm. 2021; 607:120924. doi:10.1016/j.ijpharm.2021.120924
9. Souto EB, Dias-Ferreira J, López-Machado A, Ettcheto M, Cano A, CaminsEspuny A, Espina M, Garcia ML, Sánchez-López E. Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. Pharmaceutics. 2019; 11(9): 460. doi: 10.3390/pharmaceutics11090460.
10. Zhou L, Zhan W, Wei X. Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol. 2022; 13: 1015338. doi: 10.3389/fphar.2022.1015338
11. Kagkelaris K, Panayiotakopoulos G, Georgakopoulos CD. Nanotechnology-based formulations to amplify intraocular bioavailability. Ther Adv Ophthalmol. 2022; 14: 25158414221112356. doi: 10.1177/25158414221112356.
12. Mlynek M, Trzciński JW, Ciach T. Recent Advances in the Polish Research on Polysaccharide-Based Nanoparticles in the Context of Various Administration Routes. Biomedicines. 2023; 11(5): 1307. doi: 10.3390/biomedicines11051307
13. Wu Y, Tao Q, Xie J, Lu L, Xie X, Zhang Y, Jin Y. Advances in Nanogels for Topical Drug Delivery in Ocular Diseases. Gels. 2023; 9(4): 292.doi: 10.3390/gels9040292
14. Hong SS, Oh KT, Choi HG, Lim SJ. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019; 11(10): 540. doi: 10.3390/pharmaceutics11100540
15. Guimaraes D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021; 601: 120571.doi:10.1016/j.ijpharm.2021.120571
16. Darwhekar G, Jain P, Jain DK, Agrawal G. Development and Optimization of Dorzolamide Hydrochloride and Timolol Maleate in Situ Gel for Glaucoma Treatment. Asian J. Pharm. Ana. 2011; 1(4): 93-97.doi:10.5958/2231–5675
17. Mali AD, Bathe RS. An Updated Review on Liposome Drug Delivery System. Asian J. Pharm. Res. 2015; 5(3): 151-157.doi: 10.5958/2231–5691
18. Acharya A, Goudanavar R, Vinay CH. Determination of Mucoadhesive behaviour of Timolol maleate liquid crystalline cubogel by different Techniques. Asian J. Pharm. Res. 2019; 9(1): 7-11.doi:10.5958/0975-4377.2019.00047.8
19. Nikam NR, Patil PR, Vakhariya RR, Magdum CS. Liposomes: A Novel Drug Delivery System: An Overview. Asian J. Pharm. Res. 2020; 10(1): 23-28.doi:10.5958/2231-5691.2020.00005.2
20. Matole V, Shirure P, Bedadurge A, Kadare M, Thore M. A Brief Review on Ocular Drug Delivery System. Asian J. Pharm. Res. 2021; 11(1):67-70.doi:10.5958/2231-5691.2021.00014.9
21. Ahmad W, Khan T, Basit I, Imran J. A Comprehensive Review on Targeted Drug Delivery System. Asian Journal of Pharmaceutical Research. 2022; 12(4): 335-0.doi:10.5958/2231-5691.2020.00005.2
22. Siraj MT, Thorat SM, Rayate Y, Nitalikar M. Liposome as a Drug Carrier. Asian J. Res. Pharm. Sci. 2019; 9(2): 141-147. doi:10.5958/2231-5659.2019.00021.3
23. Chavan BM, Tarade DP, Jain RS. A Short Review on Liposome. Asian Journal of Research in Pharmaceutical Sciences. 2022; 12(1): 49. doi:10.52711/2231-5659.2022.00009
24. Shinkar DM, Paralkar PS, Saudagar RB. An Overview on Trends and Developments in Liposome – as Drug Delivery System. Asian J. Pharm. Tech. 2015; 5(4): 231-237.
25. Gharge VG, Pawar P, Yadav A. Methods for Evaluation of Ocular Insert with Classification and Uses in Various Eye Diseases - A Review. Asian J. Pharm. Tech. 2017; 7 (4): 261-267. doi:10.5958/2231-5713.2017.00038.1